Kidney Cancer Clinical Trial

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

Summary

The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are:

To determine oncologic outcomes, specifically 2-year recurrence-free survival
To determine other oncologic outcomes including treatment-free, cancer-specific and overall survival
To determine time to recurrence and recurrence patterns
To determine use of adjuvant therapies
To determine perioperative complications

Participants will undergo nephroureterectomy with or without lymph node dissection. Researchers will compare these two groups to determine the oncologic efficacy of performing lymph node dissection.

View Full Description

Full Description

Upper Tract Urothelial Carcinoma (UTUC) is a rare disease with complex management. Some participants with clinically negative nodes may still receive a lymph node dissection (LND) with nephroureterectomy, and currently, no randomized controlled trial exists to evaluate the oncologic efficacy of this practice. According to current American Urologic Association guidelines, Nephroureterectomy is the standard of care intervention for high-risk UTUC and low-risk UTUC is endoscopically unresectable. The aim of the present study is to determine the efficacy, specifically 2-year recurrence-free survival, of lymph node dissection at time of nephroureterectomy for participants with UTUC, compared to no lymph node dissection, as well as examine other oncologic outcomes and complication rates

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults > 18 years
Diagnosis of UTUC as determined by upper tract biopsy (either low or high grade)
Planned for nephroureterectomy by their urologic surgeon
Disease that is ≤cT4, N0M0. Participants must have complete TNM staging prior to surgery. cT disease can be determined by biopsy of the mass (if biopsy was deep enough) or imaging (CT/MRI). cN and cM stage must be determined by preoperative imaging of the chest, abdomen and pelvis.
No concomitant muscle-invasive bladder cancer
Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Pathologically enlarged lymph nodes suspicious for metastases which would require lymph node dissection regardless of trial (>cN0)
Presence of distant metastases
Concomitant muscle invasive bladder cancer
The participant is in a reduced general condition or has a life-threatening disease.
The participant has a psychiatric disorder that precludes them from understanding the consent process.

Study is for people with:

Kidney Cancer

Estimated Enrollment:

94

Study ID:

NCT06262516

Recruitment Status:

Not yet recruiting

Sponsor:

Case Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cleveland Clinic Glickman Urological and Kidney Institute
Cleveland Ohio, 44195, United States More Info
Mohamed Eltemamy, MD
Contact
216-444-5888
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

94

Study ID:

NCT06262516

Recruitment Status:

Not yet recruiting

Sponsor:


Case Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.